BLUE - bluebird bio

-

$undefined

N/A

(N/A)

bluebird bio NASDAQ:BLUE bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

Location: | Website: www.bluebirdbio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

346.9M

Cash

144.1M

Avg Qtr Burn

-61.28M

Short % of Float

25.60%

Insider Ownership

0.54%

Institutional Own.

43.90%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.